Question · asked by 1 review
Dopamine agonist vs placebo: QoL
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings: dopamine agonists vs placebo Quality of life SMD on 2 RLS‐QoL questionnaires · patients with restless legs syndrome according to IRLSSG, 18 years or older Dopamine agonists for the treatment of restless legs syndrome (2011) · Cochrane Headline outcomes only | no estimate extracted | 17 studies · 4312 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Dopamine agonists for the treatment of restless legs syndrome 2011 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.